Literature DB >> 34263439

Physiological separation of Alzheimer's disease and Alzheimer's disease with significant levels of cerebrovascular symptomology and healthy controls.

Brian J Lithgow1,2, Zeinab Dastgheib3, Neda Anssari4, Behzad Mansouri3,4, Brian Blakley5, Mehrangiz Ashiri3, Zahra Moussavi3.   

Abstract

Most dementia patients with a mixed dementia (MxD) diagnosis have a mix of Alzheimer's disease (AD) and vascular dementia. Electrovestibulography (EVestG) records vestibuloacoustic afferent activity. We hypothesize EVestG recordings of AD and MxD patients are different. All patients were assessed with the Montreal cognitive assessment (MoCA) and Hachinski ischemic scale (HIS) (> 4 HIS score < 7 is representative of MxD cerebrovascular symptomology). EVestG recordings were made from 26 AD, 21 MxD and 44 healthy (control) participants. Features were derived from the EVestG recordings of the average field potential and field potential interval histogram to classify the AD, MxD and control groups. Multivariate analysis was used to test the features' significance. Using a leave-one-out cross-validated linear discriminant analysis with 3 EVestG features yielded accuracies > 80% for separating pairs of AD/MxD/control. Using the MoCA assessment and 2 EVestG features, a best accuracy of 81 to 91% depending on the classifier was obtained for the 3-way identification of AD, MxD and controls. EVestG measures provide a physiological basis for identifying AD from MxD. EVestG measures are hypothesized to be partly related to channelopathies and changes in the descending input to the vestibular periphery. Four of the five AD or MxD versus control features used had significant correlations with the MoCA. This supports assertions that the pathologic changes associated with AD impact the vestibular system and further are suggestive that the postulated physiological changes behind these features have an association with cognitive decline severity.
© 2021. International Federation for Medical and Biological Engineering.

Entities:  

Keywords:  Alzheimer’s disease; Biomarkers; Cerebrovascular symptomatology; Electrovestibulography; Mixed dementia; Vascular dementia

Year:  2021        PMID: 34263439     DOI: 10.1007/s11517-021-02409-8

Source DB:  PubMed          Journal:  Med Biol Eng Comput        ISSN: 0140-0118            Impact factor:   2.602


  34 in total

1.  Cerebral blood flow in dementia.

Authors:  V C Hachinski; L D Iliff; E Zilhka; G H Du Boulay; V L McAllister; J Marshall; R W Russell; L Symon
Journal:  Arch Neurol       Date:  1975-09

2.  3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease.

Authors:  Liana G Apostolova; Ivo D Dinov; Rebecca A Dutton; Kiralee M Hayashi; Arthur W Toga; Jeffrey L Cummings; Paul M Thompson
Journal:  Brain       Date:  2006-10-03       Impact factor: 13.501

3.  Plasma phospholipids identify antecedent memory impairment in older adults.

Authors:  Mark Mapstone; Amrita K Cheema; Massimo S Fiandaca; Xiaogang Zhong; Timothy R Mhyre; Linda H MacArthur; William J Hall; Susan G Fisher; Derick R Peterson; James M Haley; Michael D Nazar; Steven A Rich; Dan J Berlau; Carrie B Peltz; Ming T Tan; Claudia H Kawas; Howard J Federoff
Journal:  Nat Med       Date:  2014-03-09       Impact factor: 53.440

4.  CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease.

Authors:  R Perneczky; A Tsolakidou; A Arnold; J Diehl-Schmid; T Grimmer; H Förstl; A Kurz; P Alexopoulos
Journal:  Neurology       Date:  2011-06-22       Impact factor: 9.910

5.  Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.

Authors:  Liang Wang; Tammie L Benzinger; Yi Su; Jon Christensen; Karl Friedrichsen; Patricia Aldea; Jonathan McConathy; Nigel J Cairns; Anne M Fagan; John C Morris; Beau M Ances
Journal:  JAMA Neurol       Date:  2016-09-01       Impact factor: 18.302

6.  Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

Authors:  G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

7.  Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria.

Authors:  Michael Grundman; Keith A Johnson; Ming Lu; Andrew Siderowf; Grazia Dell'Agnello; Anupa K Arora; Daniel M Skovronsky; Mark A Mintun; Michael J Pontecorvo
Journal:  Dement Geriatr Cogn Disord       Date:  2016-01-08       Impact factor: 2.959

8.  Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.

Authors:  Sebastiaan Engelborghs; Karen De Vreese; Tom Van de Casteele; Hugo Vanderstichele; Bart Van Everbroeck; Patrick Cras; Jean-Jacques Martin; Eugeen Vanmechelen; Peter Paul De Deyn
Journal:  Neurobiol Aging       Date:  2007-04-10       Impact factor: 4.673

9.  Routine lumbar puncture for the early diagnosis of Alzheimer's disease. Is it safe?

Authors:  Manuel Menéndez-González
Journal:  Front Aging Neurosci       Date:  2014-04-09       Impact factor: 5.750

10.  Mixed dementia: A review of the evidence.

Authors:  Nilton Custodio; Rosa Montesinos; David Lira; Eder Herrera-Pérez; Yadira Bardales; Lucía Valeriano-Lorenzo
Journal:  Dement Neuropsychol       Date:  2017 Oct-Dec
View more
  2 in total

1.  An unbiased algorithm for objective separation of Alzheimer's, Alzheimer's mixed with cerebrovascular symptomology, and healthy controls from one another using electrovestibulography (EVestG).

Authors:  Zeinab A Dastgheib; Brian J Lithgow; Zahra K Moussavi
Journal:  Med Biol Eng Comput       Date:  2022-01-31       Impact factor: 2.602

2.  Verification EVestG recordings are vestibuloacoustic signals.

Authors:  Brian Blakley; Mehrangiz Ashiri; Zahra Moussavi; Brian Lithgow
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-07-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.